Enterome

🔬 Our Innovative Approach to Cancer Therapy Highlighted in MedNous!🌟 Enterome's pioneering work to improve clinical outcomes for patients thanks to a unique immunotherapy is featured in an insightful article in MedNous (Evernow Publishing Ltd). The article, titled "Enterome: A microbiome approach to cancer therapy," delves into our unique OncoMimics™ technology, which utilizes synthetic peptides derived from bacterial proteins to stimulate a robust immune response against cancer cells. MedNous reporter, Victoria English, describes our flagship product, EO2463, and its promising results in treating indolent non-Hodgkin lymphoma. OncoMimics™ Technology: Our synthetic, bacteria-derived peptides mimic tumor-associated antigens (TAAs) to activate pre-existing memory T cells, providing a rapid and sustained immune response. EO2463 Clinical Trials: Initial results from our SIDNEY trial show significant tumor reduction and high rates of complete remission in patients with relapsed/refractory non-Hodgkin lymphoma. Strategic Vision: Our goal is to develop therapies that outperform existing treatments in generating effective and long-lasting immune responses. Thank you Victoria for featuring our work and allowing us to share this exciting development! 👉 See attached the full article (Published in the June 2024 edition of MedNous, a publication of Evernow Publishing Ltd). Stay tuned for more updates on our journey to revolutionize cancer therapy. #CancerTherapy #Immunotherapy ##OncoMimics™ #Enterome

We recently presented data on our innovative OncoMimics™ peptide-based cancer immunotherapy at the #EACR2024 Annual Congress. Swipe through the carrousel below to learn more 👇

The exciting work of LLS TAP partners continues although #ASCO24 has come and gone. Our partners at Caribou Biosciences, Enterome, Kymera Therapeutics, and MorphoSys presented promising treatment results across a variety of blood cancers, including non-Hodgkin lymphoma and myelofibrosis. See how LLS TAP continues to help accelerate the development of these treatments to change the standard of care 👉 https://bit.ly/3KSWXGL

Keeping the immune system engaged in suppressing tumors for the long term: this is what Enterome aims to achieve for patients with Non-Hodgkin Lymphoma using EO2463, our novel immune therapy currently being evaluated in the phase 2 SIDNEY trial. EO2463 targets multiple tumor antigens simultaneously, allowing the immune system to recognize the tumor cells to a far greater degree and, therefore, engage more effectively with the malignancy. Watch the insightful interview of Dr. Stephen Ansell from the Mayo Clinic on Video Journal of Hematology & Hematological Oncology (VJHemOnc) to learn more about our advancements in cancer immunotherapy #CancerResearch #Immunotherapy #NHL #OncoMimics #Enterome

If you are at EACR 2024 annual congress, let’s meet at my poster, board P-285.

Today we are glad to announce our upcoming poster presentation at the Annual Congress of the European Association for Cancer Research (#EACR2024). Our colleague Alice Talpin - Le Borgne will present data on Enterome's innovative OncoMimics™ peptide-based immunotherapy, designed to harness the patient’s immune system to target and eliminate cancer cells. OncoMimics™ peptides compose our clinical-stage treatments EO2463 (evaluated in non-Hodgkin lymphoma) and EO2401 (evaluated in recurrent glioblastoma, and adrenal tumors). “The OncoMimics™ approach offers a promising strategy to enhance cancer immunity by overcoming the limitations of current vaccines. Our preclinical and clinical data underscore the ability of OncoMimics™ peptides to elicit strong, durable immune responses, which could significantly improve patient outcomes”, explains Alice. Poster 1155 Presentation details: Title: Innovative immunotherapy based on commensal-derived peptides for enhancing CD8+ T cell activation against Tumor-Associated Antigens Presenting Author: Alice Talpin, PhD, Enterome researcher Poster Session: Immunotherapy (odd Abstract Numbers) Poster Board: P-285 Session Date and Time: June 12, 18:40 to 20:15 CET (poster displayed from 11:00 CET) Read the full press release here: https://lnkd.in/eA_NTjqn

We are excited to announce that our seminal paper, marking the development of the first applicable peptide immunotherapy using bacteria-derived peptides to treat cancer, is now available on bioRxiv: https://lnkd.in/eCD2KJEM   Providing the foundation for our EO2463 and EO2401 immune therapies, our OncoMimics™ immunotherapy approach leverages molecular mimicry between commensal bacterial peptides and tumor-associated antigens to induce robust, cross-reactive CD8+ T cell responses against tumors.   We hope you enjoy the read, as this is the first of a planned series. Thank you to all our co-authors!   #Enterome #OncoMimics™ #peptides #Biotechnology #Innovation #Immunotherapy #ImmunoOncology #bioRxiv

Belichard Pierre, Enterome’s co-founder and Chief Executive Officer, and Christelle Dumoussaud, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, on June 4-6, 2024. Please reach out to Christelle or Pierre to request a meeting! #JefferiesHealthcare

Coming to Chicago? Curious about potential novel therapeutic options for patients with indolent non-Hodgkin lymphoma? Don't leave ASCO24 without checking out the results of the SIDNEY clinical trial evaluating our lead compound, EO2463!

#ASCO24 is just one week away! We are thrilled to report promising findings from the SIDNEY clinical trial of EO2463 for indolent non-Hodgkin lymphoma at this year's meeting. In the first cohort from the study, beneficial clinical responses were observed with EO2463 monotherapy already at 6 weeks of treatment, and Complete Response rate of 78% in patients treated with EO2463 upon addition of the SoC. Read more: https://lnkd.in/e-p5ndQA